Should FDA prioritize more tropical disease drugs?
Executive Summary
FDA will hold a public hearing Dec. 12 soliciting input on adding additional diseases to the list of tropical diseases for which sponsors developing corresponding treatments could receive priority review vouchers. FDA is authorized under FDAAA to award the vouchers to sponsors of certain tropical disease product applications, but states in a recent draft guidance that those applications could not be reviewed until it receives congressional authorization to collect a special user fee to support the program (1"The Pink Sheet," Oct. 27, 2008, p. 28). Requests to deliver oral presentations and comments at the public hearing must be submitted by Nov. 17
You may also be interested in...
Priority Review Vouchers One Step Closer, But Congress Must Act Again
FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.